



(11) **EP 1 743 642 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

Note: Bibliography reflects the latest situation

(15) Correction information:

**Corrected version no 1 (W1 A1)**  
**INID code(s) 72**

(51) Int Cl.:

**A61K 31/4155** <sup>(2006.01)</sup> **A61K 31/496** <sup>(2006.01)</sup>  
**A61K 31/454** <sup>(2006.01)</sup>

(48) Corrigendum issued on:

**25.04.2007 Bulletin 2007/17**

(43) Date of publication:

**17.01.2007 Bulletin 2007/03**

(21) Application number: **05384024.5**

(22) Date of filing: **15.07.2005**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI  
SK TR**

Designated Extension States:

**AL BA HR MK YU**

(71) Applicant: **LABORATORIOS DEL DR. ESTEVE,  
S.A.**

**08041 Barcelona (ES)**

(72) Inventor: **Buschmann, Helmut Heinrich**

**08960 Sant Just Desvern (Barcelona) (ES)**

(54) **Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases**

(57) The present invention relates to the use of substituted pyrazoline compounds, their derivatives as well as their physiologically acceptable salts, in medicinal products for human therapeutics and/or animal research

for the treatment of a variety of diseases associated the cannabinoid receptor system in humans and animals.

**EP 1 743 642 A8**